Catalent (NYSE:CTLT) Downgraded to “Sell” Rating by StockNews.com

StockNews.com downgraded shares of Catalent (NYSE:CTLT) from a hold rating to a sell rating in a research report released on Wednesday morning.

Several other research firms have also issued reports on CTLT. Robert W. Baird restated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $59.83.

Catalent Stock Performance

NYSE CTLT opened at $59.95 on Wednesday. The firm’s fifty day moving average price is $60.03 and its two-hundred day moving average price is $58.03. The stock has a market cap of $10.88 billion, a PE ratio of -10.92, a PEG ratio of 2.06 and a beta of 1.16. Catalent has a fifty-two week low of $32.38 and a fifty-two week high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the firm earned ($0.10) EPS. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. On average, equities analysts expect that Catalent will post 0.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Catalent news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.31% of the stock is owned by insiders.

Institutional Trading of Catalent

Institutional investors and hedge funds have recently made changes to their positions in the stock. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Catalent during the 2nd quarter valued at $42,000. Sentry Investment Management LLC bought a new position in shares of Catalent during the 3rd quarter valued at $53,000. Longfellow Investment Management Co. LLC grew its holdings in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares during the last quarter. Finally, Intact Investment Management Inc. bought a new position in shares of Catalent during the 3rd quarter valued at $73,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.